pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,873 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1893Endpoints1466Fierce Biotech779BioSpace767BioPharma Dive555raps257onclive165fda recalls
therapy area
allOncology13097Rare Disease3399Immunology3069Cardiology2869Hematology2336Pulmonology2300Vaccines
  • Drugmakers urged to assess device capabilities and engage regulators early for combo products
    At the AFDO/RAPS Combination Products Summit, a panel of experts advised drugmakers that developing standalone medical devices to be used with their drugs requires careful evaluation of the devices…
    raps · 2d agoRegulatoryNeutral↗ source
  • Early Alert: B. Braun Medical Inc. Updates Use Instructions for Caresite Micro Luer Access Device
    BBMI corrects Caresite devices due to issue with internal piston remaining depressed following disconnection, preventing the valve from fully closing.
    fda medwatch · 2d agoRegulatoryNeutral↗ source
← prev
page 2 of 75
next →
126
fda medwatch117
globenewswire health73
fda press62
1892
Psychiatry & CNS1247
Ophthalmology1150
Endocrinology & Metabolism809
Pain801
Nephrology789
  • UK MHRA launches AdvanceGxP to help drugmakers address good practice early
    The Medicines and Healthcare products Regulatory Agency in the United Kingdom has introduced a new service called AdvanceGxP. The initiative is designed to give pharmaceutical companies early guida…
    raps · 2d agoRegulatoryNeutral↗ source
  • FDA issues final guidance on 510(k) ownership transfers, shortening sections and adding Q&A
    The U.S. Food and Drug Administration has released a final guidance that spells out the duties of owners of 510(k) clearances when a product is sold or transferred to another company. The new docu…
    raps · 2d agoRegulatoryNeutral↗ source
  • Survey finds most users find home diagnostic tests very helpful, but only a third view them as very accurate
    Det Norske Veritas (DNV) surveyed 12,500 people in 17 countries to gauge attitudes toward home diagnostic tests and other medical devices used at home. Among respondents who had used home diagnost…
    Fierce Biotech · 2d agoNeutral↗ source
  • Pfizer signs $2.6 billion deal with China's Starna to acquire in vivo CAR-T programs for autoimmune diseases
    Pfizer announced a $2.6 billion agreement with Chinese biotech Starna Therapeutics to obtain rights to three preclinical in vivo CAR-T candidates aimed at autoimmune diseases. The deal includes a…
    Fierce Biotech · 3d agoDealPositive↗ source
  • Pfizer signs $2.6 billion China deal to develop in-vivo CAR-T therapies for autoimmune disease
    Pfizer announced a collaboration with Chinese biotech Starna Therapeutics to pursue in-vivo CAR-T cell therapies aimed at autoimmune disorders. Under the agreement, Pfizer will receive exclusive r…
    BioPharma Dive · 2d agoDealPositive↗ source
  • AbbVie inks up to $2.5 billion deal with Disco to pursue bispecific cancer therapeutics
    AbbVie announced a collaboration with German biotech Disco Pharmaceuticals that could be worth up to $2.5 billion. The agreement provides a $40 million upfront payment, with the balance linked to…
    Fierce Biotech · 2d agoDealPositive↗ source
  • Biogen's tau antisense therapy shows 38% slower decline in 2-year Alzheimer extension study
    Biogen presented new data from the open‑label extension of its phase 2 Celia trial at the CTAD 2026 conference. The update focused on the tau‑targeting antisense oligonucleotide, diranersen, admini…
    Fierce Biotech · 3d agoPositive readoutPositive↗ source
  • Priavoid’s Alzheimer’s drug misses primary goal in phase 2 trial, shows later cognitive benefit signal
    German biotech Priavoid reported that its oral all-D-peptide candidate, PRI-002, did not achieve the primary efficacy endpoint in the phase 2 PRImus-AD study of patients with mild cognitive impairm…
    Fierce Biotech · 3d agoNegative readoutNegative↗ source
  • Cognito Therapeutics' Phase 3 HOPE Study Misses Primary Goal but Shows Promise in Mild Alzheimer’s Patients
    Cognito Therapeutics announced that its phase 3 HOPE trial of Spectris AD, a home-based device delivering light and sound stimulation, did not achieve its primary efficacy endpoint. The trial enro…
    Fierce Biotech · 3d agoNegative readoutNeutral↗ source
  • FDA rejects Summit Therapeutics' lung cancer drug ivonescimab, citing insufficient survival benefit
    The U.S. Food and Drug Administration issued a complete response letter rejecting the lung‑cancer therapy ivonescimab, which is being developed by Summit Therapeutics in partnership with Akeso. In…
    BioPharma Dive · 2d agoRegulatoryNegative↗ source
  • FDA clears Medtronic's MiniMed Fit tubeless insulin pump
    MiniMed, a Medtronic unit, announced that the FDA has granted clearance for its new tubeless insulin pump called MiniMed Fit. The device is designed to be worn for up to seven days and holds a 300…
    Fierce Biotech · 3d agoApprovalPositive↗ source
  • Merck halts $2.7 billion BTK inhibitor program after negative phase 3 data
    Merck announced it is discontinuing its BTK inhibitor nemtabrutinib program, ending three phase 3 trials in chronic lymphocytic leukemia and small lymphocytic lymphoma. The decision follows a reco…
    Fierce Biotech · 3d agoNegative readoutNegative↗ source
  • Big Pharma execs urge biotech firms to be transparent and patient to win deals
    At Fierce Biotech's London Life Sciences Week, representatives from five major pharmaceutical companies shared how they evaluate biotech partners. Bayer's head of business development warned that…
    Fierce Biotech · 3d agoDealNeutral↗ source
  • Experts warn of safety risks as FDA targets compounded GLP-1 weight-loss drugs sold by telehealth firms
    At the HLTH conference, experts highlighted growing concerns about telehealth companies that sell compounded GLP-1 weight-loss medications. These firms create custom formulations and ship them dir…
    BioPharma Dive · 2d agoRegulatoryNegative↗ source
  • Crown Biosciences remains independent after $204 million Adicon acquisition collapses
    Crown Biosciences, a contract research organization, will continue operating on its own after a planned sale to China's Adicon did not close. The parties announced on Nov 16 that they were ending…
    Fierce Biotech · 3d agoDealNegative↗ source
  • Quanterix CEO Everett Cunningham resigns after ten months, interim leader appointed
    Quanterix announced that Everett Cunningham will leave his role as president and chief executive officer after serving less than a year. The company said he will step down to pursue another opportu…
    Fierce Biotech · 3d agoNeutral↗ source
  • White House pulls nomination for FDA nominee Overton
    The sudden end of Heidi Overton’s candidacy likely ensures a Democrat-controlled Congress will choose the FDA’s next leader — but shouldn’t disrupt the agency, analysts say.
    BioPharma Dive · 2d ago↗ source
  • FDA clears Roche's Wilserdly pill for certain ER-positive, HER2-negative breast cancers
    The U.S. Food and Drug Administration has approved Roche's new oral therapy Wilserdly for a specific group of breast cancer patients. The drug is indicated for adults with estrogen receptor‑positi…
    BioPharma Dive · 3d agoApprovalPositive↗ source
  • Isomorphic Labs secures $5 billion Series C, doubling its recent $2.1 billion raise
    Isomorphic Labs, an AI‑driven drug discovery startup spun out of DeepMind, announced a $5 billion Series C financing, marking its second multibillion‑dollar round within six months. The funding fo…
    Fierce Biotech · 4d agoDealPositive↗ source
  • Eli Lilly inks $5.9 billion partnership with Stipple Bio to develop precision oncology drugs
    Eli Lilly has announced a partnership with Stipple Bio that could be worth up to $5.9 billion. The collaboration will focus on oncology drug candidates designed to target tumor cells more precisely…
    Fierce Biotech · 4d agoDealPositive↗ source
  • White House withdraws Heidi Overton’s FDA nomination hours before Senate vote
    The White House has reportedly withdrawn the nomination of Dr. Heidi Overton, who was slated to become the FDA’s next commissioner, just hours before the Senate HELP Committee was set to vote. Ove…
    Fierce Biotech · 3d agoRegulatoryNegative↗ source
  • FDA rejects Summit’s ivonescimab, citing China‑centric data and missed survival benefit
    The FDA sent Summit Therapeutics a complete response letter on Nov 13, rejecting its PD‑1×VEGF bispecific antibody ivonescimab. Reviewers said the pivotal HARMONi trial was dominated by patients f…
    Fierce Biotech · 3d agoCRLNegative↗ source
  • AI drugmaker Isomorphic Labs raises $5 billion in Series C round
    Isomorphic Labs, an Alphabet spinout that applies artificial intelligence to drug discovery, announced a $5 billion Series C financing. The round was led by Greenoaks and Sequoia Capital, with Alp…
    BioPharma Dive · 3d agoDealPositive↗ source